On February 5, 2024, the WeFlow-Bibranch™ Dual Embedded Branched Thoracic Aortic Overlay Stent System (“WeFlow-Bibranch™”), which was developed and manufactured by Hangzhou Weijiang Medical Technology Co. (“WeFlow-Bibranch™”), developed and manufactured by Weqiang Medical Technology Co., Ltd (“Weqiang Medical”), completed the last enrollment in the General Hospital of the People's Liberation Army of China.
Thus, WeFlow-Bibranch™ China Registry Clinical Trial and GIANT Study (Guo's aortIc Arch recoNstrucTion, Clinical Trial Registration No. NCT04769992) enrollment was perfectly concluded!
This signifies that the first modular product in China to treat aortic arch lesions via endoluminal treatment has now reached a key milestone point and is one big step closer to market!
The GIANT study is a prospective, multicenter clinical registry study led by the First Medical Center of PLA General Hospital, with Prof. Guo Wei as the PI, aimed at evaluating the safety and efficacy of the modular inlay aortic arch stenting system for the treatment of aortic arch lesions. Follow-up showed that the WeFlow-Bibranch™ had significant clinical efficacy and excellent performance, and the overall results were satisfactory!
Aortic arch disease has always been a challenge for endoluminal interventions due to its complex anatomy, and the main challenge is how to ensure that the aortic arch lesions are isolated and at the same time, the branching vessels of the arch are kept open.
The WeFlow-Bibranch™ dual inline branch stent system consists of an inline ascending main stent system, an arch segmental stent system, and a branch stent system. The inline ascending main stent provides sufficient anchorage for the arch stent and the branch stent, and the junctions are tightly articulated to avoid endoleak; step-by-step implantation allows for the cerebral blood supply to be maintained at all times, and the modular design maximizes the ability to meet The modular design can maximize the satisfaction of clinical differences. This product is expected to become another favorable tool for the treatment of aortic arch lesions!
Introduction of experts
Prof. Wei Guo
Professor and Director of the All-Army Vascular Surgery Center of the Vascular Surgery Department of the General Hospital of the People's Liberation Army, People's Liberation Army Medical College and Tsinghua University.
Nankai University, Ph.D. (post) supervisor
Long-term clinical, scientific research, teaching and health care in vascular diseases
Specialist in consultation with the Central Health Board,
Director of the Vascular Medicine Specialized Committee of the Chinese Society of Research Hospitals,
Director of Vascular Devices Branch, China Medical Device Industry Association,
Vice Chairman, Vascular Surgery Division Committee, Surgical Branch, Chinese Physicians' Association,
Vice Chairman of the Vascular Surgery and Bioengineering Division of the Chinese Medical Association,
Vice Chairman of Vascular Surgery Specialized Committee of Cross-Strait Medical Technology Exchange Society,
Vice Chairman of Vascular Surgery Specialized Committee of China Medical Promotion Committee,
Vice Chairman, Vascular Specialized Committee, Chinese Society of Geriatrics,
Expert in reviewing scientific research topics of the Ministry of Science and Technology,
Expert of Beijing Medical Accident Appraisal Committee.
He has been awarded 13 national patents, 12 national and provincial and ministerial level projects; 1 first prize of National Scientific and Technological Progress, 1 first prize of Beijing Scientific and Technological Achievements, 1 first prize of Army Medical Achievements, 1 first prize of Beijing Medical Prize, and 1 second prize of Army Medical Achievements.
Main Contributions: Since 1997, he has been the first in China to perform endoluminal repair of abdominal aortic aneurysm, aortic coarctation, and thoracic aortic aneurysm; the first to perform hybrid surgery for complex aortic aneurysm and coarctation; and the first to perform endoluminal and hybrid surgical treatments for peripheral arterial stenosis or occlusion, etc. He has been invited to provide live broadcasting for the renowned LINC Congress (Germany), the C3 Conference (USA), and CICE Congress (South America), etc., for twelve years in a row since 2008. For 12 consecutive years since 2008, he has been invited to perform live surgery for the prestigious LINC congress (Germany), live surgery for the C3 conference (USA), and live surgery for the CICE congress in South America. He has been the host, speaker and coordinator of Veith, VIVA, SVS in the USA, LINC and CharingCross in Europe for many times. The International Course on Endoluminal Repair of the Aorta is held annually and has trained more than 120 foreign experts from 11 countries. He has organized and participated in many international and national large-scale epidemiological and clinical multicenter studies.
